Clinical Trials Browser

Approved for marketing × 1 year × Clear all

NCT06877676 2026-04-13

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

Approved for marketing

Non-Muscle Invasive Bladder Neoplasms

NCT04507503 2026-03-10

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Approved for marketing

Gastrointestinal

Cholangiocarcinoma

NCT05757973 2025-12-09

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Approved for marketing

Multiple Myeloma, Recurrence

NCT06132191 2025-11-20

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Approved for marketing

DermatologicThoracic

Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung

NCT05164250 2025-11-10

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Approved for marketing

Multiple Myeloma, Recurrence

NCT05162443 2025-08-26

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

Approved for marketing

Neoplasm Metastasis, Neoplasms

NCT04617002 2025-08-20

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Approved for marketing

Glioma

NCT06279728 2025-07-03

Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

Approved for marketing

EGFRm Advanced Non-Small Cell Lung Cancer

NCT04220203 2025-06-26

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

Approved for marketing

HER2-positive Breast Cancer

NCT05463939 2025-06-15

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Approved for marketing

Multiple Myeloma, Recurrence

NCT03825484 2025-06-13

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

Approved for marketing

Advanced Cancers and FGFR Genetic Alterations

NCT04599712 2025-06-13

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Approved for marketing

Carcinoma, Non-Small-Cell Lung

NCT05401214 2025-06-13

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

Approved for marketing

Metastatic Castration-resistant Prostate Cancer

NCT04100694 2025-05-20

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Approved for marketing

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma